DELRAY BEACH, Fla., June 22, 2017 (GLOBE NEWSWIRE) — PositiveID Corporation (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that it has completed the development of the Caregiver® thermometer with Bluetooth® and has achieved qualification and listing from the Bluetooth Special Interest Group (SIG) following the successful completion of testing. PositiveID now intends to initiate marketing efforts for the Bluetooth-enabled version of Caregiver.
PositiveID’s FDA-cleared Caregiver is a professional grade, infrared thermometer for measurement of forehead temperature without contact in adults, children, and infants. Caregiver with Bluetooth can connect wirelessly to electronic health records systems and patient monitoring stations in hospitals. Caregiver is marketed by Thermomedics, Inc., a wholly owned subsidiary of PositiveID.
Caregiver delivers an oral-equivalent temperature directly from the forehead in one to two seconds. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs. It is estimated that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone.
“We believe achieving Bluetooth qualification and listing for our latest model of Caregiver is an important milestone that will help us propel the growth of this business,” said Gary O’Hara, Chief Technology Officer of Thermomedics. “By offering wireless connectivity to the most frequently used hospital systems we believe we can forge new partnerships and gain market share.”
The new Caregiver Bluetooth-enabled thermometer uses the low energy version Bluetooth 4.0 known as “Bluetooth Smart” for maximum battery life. This new capability of the Bluetooth-enabled version of Caregiver to interface with certain electronic health record systems will be a premium addition to the standard product offering.
PositiveID markets its Caregiver thermometer in the fastest growing segment of the global temperature monitoring device market, infrared thermometry. The global market for temperature monitoring devices is forecast to reach $1 billion by 2020, with infrared thermometers experiencing the fastest growth driven in part by concerns over the spread of highly infectious diseases like Ebola, according to Global Industry Analysts, Inc.
About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.
Statements about PositiveID’s (the “Company”) future expectations, including the likelihood that the Company now intends to initiate marketing efforts for the Bluetooth-enabled version of Caregiver; the likelihood that the global market for temperature monitoring devices is forecast to reach $1 billion by 2020, with infrared thermometers experiencing the fastest growth driven in part by concerns over the spread of highly infectious diseases like Ebola; the likelihood that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone; the likelihood that achieving Bluetooth qualification and listing for the latest model of Caregiver is an important milestone that will help the Company propel the growth of this business; the likelihood that by offering wireless connectivity to the most frequently used hospital systems the Company believes it can forge new partnerships and gain market share; constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID’s actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the professional healthcare market, as well as other risks. Additional information about these and other factors that could affect the Company’s business is set forth in the Company’s various filings with the Securities and Exchange Commission, including those set forth in the Company’s 10-K filed on April 12, 2016, and 10-Qs filed on November 18, 2016, August 12, 2016, and May 16, 2016, under the caption “Risk Factors.” The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT: Contacts: PositiveID Corporation Allison Tomek (561) 805-8044 firstname.lastname@example.org Paul Knopick E & E Communications 940.262.3584 email@example.com